From the Editor-in-Chief

Surrogate endpoints can speed up drug approvals, but are they valid measures of effectiveness?

by William G. Nelson, MD, PhD

Forward Look

As patents expire on biologic drugs, cancer patients get new options.

by Stephen Ornes

Policy Matters

The AACR and the FDA presented joint recommendations that include broadening clinical trial eligibility and engaging the community in clinical trial recruitment.

by Kenneth C. Anderson, MD; Lola A. Fashoyin-Aje, MD, MPH; Nicole Gormley, MD; and Paul G. Kluetz, MD

Q&A

In her first book, journalist and breast cancer survivor Kate Pickert traces the winding road of cancer research and patient advocacy.

by Marci A. Landsmann

People with cancer can pay significant costs for parking at cancer centers while receiving their treatment, a study finds.

by Marcus A. Banks

Survivor Profile

Diagnosed with two cancers prior to turning 40, Rebecca Esparza uses her voice to advocate for policy changes to help people affected by cancer.

by Lindsey Konkel

Using robotic assistants for cancer surgery has become commonplace. Whether cancer patients benefit when a surgeon uses a robot remains unclear.

by Sue Rochman

My diagnosis with colorectal cancer at age 32 affected my fertility. As a result of my experiences, I help others who have been diagnosed with cancer understand their choices related to fertility preservation and their options for becoming a parent.

by Allison Rosen

NCI Director Norman E. “Ned” Sharpless addresses disparities and maps out plans for the future amid “profound upheaval.”

by Kevin McLaughlin

Following the arrival of the coronavirus in the U.S., people with cancer and their doctors are adjusting to new ways of doing things while continuing to seek and provide cancer care.

by Kate Yandell